Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy

Documenta Ophthalmologica

Volumn 124, Issue 3, 2012, Pages 225-236

  Messias, André ^a   Filho, José Afonso Ramos ^a   Messias, Katharina ^a   Almeida, Felipe P P ^a   Costa, Rogério A ^a   Scott, Ingrid U ^b   Gekeler, Florian ^c   Jorge, Rodrigo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Angiogenesis; Diabetes; Electroretinography; Laser treatment; Vascular endothelial growth factor (VEGF)

Indexed keywords

FLUORESCEIN; HEMOGLOBIN A1C; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

A WAVE; ADJUVANT THERAPY; ADULT; AMPLITUDE MODULATION; AREA UNDER THE CURVE; ARTICLE; B WAVE; CLINICAL ARTICLE; CONTROLLED STUDY; DARK ADAPTATION; DIABETIC RETINOPATHY; DISEASE DURATION; ELECTRORETINOGRAPHY; EVALUATION STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LASER COAGULATION; LIGHT ADAPTATION; MALE; OSCILLATORY POTENTIAL; PANRETINAL PHOTOCOAGULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHOTOSTIMULATION; PHYSIOLOGY; RETINA ROD;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DARK ADAPTATION; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MALE; MIDDLE AGED; PHOTIC STIMULATION; RETINAL ROD PHOTORECEPTOR CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84865065679     PISSN: 00124486     EISSN: 15732622     Source Type: Journal    
DOI: 10.1007/s10633-012-9322-5     Document Type: Article

References (41)

1. Klein R (1992) Retinopathy in a population-based study. Trans Am Ophthalmol Soc 90:561-594
2. ETDRSResearchGroup (1991) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early treatment diabetic retinopathy study research group. Ophthalmology 98:823-833
3. Vander JF, Duker JS, Benson WE, Brown GC, McNamara JA, Rosenstein RB (1991) Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 98:1575-1579
4. Flynn HW Jr, Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL 3rd (1992) Pars plana vitrectomy in the early treatment diabetic retinopathy study. ETDRS report number 17. The early treatment diabetic retinopathy study research group. Ophthalmology 99:1351-1357
5. ETDRSResearchGroup (1991) Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early treatment diabetic retinopathy study research group. Ophthalmology 98:766-785
6. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487
7. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450
8. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
9. Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, Bayard F, Plouet J (1994) Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112:1476-1482
10. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGFreceptor chimeric proteins. Proc Natl Acad Sci USA 92: 10457-10461
11. Matsuyama K, Ogata N, Jo N, Shima C, Matsuoka M, Matsumura M (2009) Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn J Ophthalmol 53:243-248
12. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M (2007) Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 125:1363-1366
13. Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr, Davis MD, Goldbaum M, Gonzales C, Guyer DR, Barrett K, Patel M, Macugen Diabetic Retinopathy Study G (2006) Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113:23-28
14. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM (2006) A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113: 1706-1712
15. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD, Macugen Diabetic Retinopathy Study G (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112: 1747-1757
16. Jardeleza MS, Miller JW (2009) Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol 24:87-92
17. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU (2006) Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26:1006-1013
18. Jorge R, Oliveira RS, Messias A, Almeida FP, Strambe ML, Costa RA, Scott IU (2011) Ranibizumab for retinal neovascularization. Ophthalmology 118(1004-1004):e1001
19. Diabetic Retinopathy Clinical Research N, Googe J, Brucker AJ, Bressler NM, Qin H, Aiello LP, Antoszyk A, Beck RW, Bressler SB, Ferris FL III, Glassman AR, Marcus D, Stockdale CR (2011) Randomized trial evaluating shortterm effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 31:1009-1027
20. Filho JA, Messias A, Almeida FP, Ribeiro JA, Costa RA, Scott IU, Jorge R (2011) Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol 89:e567-e572
21. Tzekov R, Arden GB (1999) The electroretinogram in diabetic retinopathy. Surv Ophthalmol 44:53-60
22. Matsui Y, Katsumi O, Sakaue H, Hirose T (1994) Electroretinogram b/a wave ratio improvement in central retinal vein obstruction. Br J Ophthalmol 78:191-198
23. Capoferri C, Bagini M, Chizzoli A, Pece A, Brancato R (1990) Electroretinographic findings in panretinal photocoagulation for diabetic retinopathy. A randomized study with blue-green argon and red krypton lasers. Graefes Arch Clin Exp Ophthalmol 228:232-236
24. Perlman I, Gdal-On M, Miller B, Zonis S (1985) Retinal function of the diabetic retina after argon laser photocoagulation assessed electroretinographically. Br J Ophthalmol 69:240-246
25. Frank RN (1975) Visual fields and electroretinography following extensive photocoagulation. Arch Ophthalmol 93:591-598
26. Shetty R, Pai SA, Vincent A, Shetty N, Narayana KM, Sinha B, Shetty BK (2008) Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 116:129-135
27. ETDRS Research Group (1979) Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. The diabetic retinopathy study research group. Arch Ophthalmol 97:654-655
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT Jr., Roccella EJ, National Heart L, Blood Institute Joint National Committee on Prevention DE, Treatment of High Blood P, National High Blood Pressure Education Program Coordinating C (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560-2572
29. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M, International Society for Clinical Electrophysiology of V (2009) ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 118:69-77
30. Naka KI, Rushton WA (1966) S-potentials from luminosity units in the retina of fish (Cyprinidae). J Physiol 185:587-599
31. ETDRSResearchGroup (1987) Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: early treatment diabetic retinopathy study report no. 3. The early treatment diabetic retinopathy study research group. Int Ophthalmol Clin 27:254-264
32. ETDRS Research Group (1985) Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. early treatment diabetic retinopathy study research group. Arch Ophthalmol 103:1796-1806
33. Scholl HP, Zrenner E (2000) Electrophysiology in the investigation of acquired retinal disorders. Surv Ophthalmol 45:29-47
34. Luu CD, Szental JA, Lee SY, Lavanya R, Wong TY (2010) Correlation between retinal oscillatory potentials and retinal vascular caliber in type 2 diabetes. Invest Ophthalmol Vis Sci 51:482-486
35. Lecleire-Collet A, Audo I, Aout M, Girmens JF, Sofroni R, Erginay A, Le Gargasson JF, Mohand-Said S, Meas T, Guillausseau PJ, Vicaut E, Paques M, Massin P (2011) Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy. Invest Ophthalmol Vis Sci 52:2861-2867
36. Holopigian K, Greenstein VC, Seiple W, Hood DC, Carr RE (1997) Evidence for photoreceptor changes in patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 38:2355-2365
37. Breton ME, Quinn GE, Keene SS, Dahmen JC, Brucker AJ (1989) Electroretinogram parameters at presentation as predictors of rubeosis in central retinal vein occlusion patients. Ophthalmology 96:1343-1352
38. Chung NH, Kim SH, Kwak MS (1993) The electroretinogram sensitivity in patients with diabetes. Korean J Ophthalmol 7:43-47
39. Ogden TE, Callahan F, Riekhof FT (1976) The electroretinogram after peripheral retinal ablation in diabetic retinopathy. Am J Ophthalmol 81:397-402
40. Slaughter MM, Miller RF (1981) 2-amino-4-phosphonobutyric acid: a new pharmacological tool for retina research. Science 211:182-185
41. Nilsson SE (1971) Human retinal vascular obstructions. A quantitative correlation of angiographic and electroretinographic findings. Acta Ophthalmol (Copenh) 49:111-133